How Much Does Belsomra Cost in Maryland in 2026?

Maryland Retail Pricing Breakdown

The average cash price for a 30-day supply of Belsomra across Maryland retail pharmacies sits around $85 in 2026, a significant reduction from the $340 list price set by Merck. This gap exists because of negotiated pharmacy benefit manager rates and competitive pricing among chains.

Pricing varies by location within the state. Pharmacies in the Baltimore metro area and Washington, D.C. suburbs tend to cluster near the $85 average, while independent pharmacies in western Maryland or the Eastern Shore may quote slightly higher or lower depending on their wholesale agreements. The 10 mg and 20 mg tablets are typically priced identically at retail. GoodRx and similar aggregators show Maryland-specific pricing that fluctuates weekly, so checking multiple sources before filling remains worthwhile.

Suvorexant received FDA approval in 2014 as the first dual orexin receptor antagonist for insomnia treatment [1]. The key trial by Herring et al. (2014) enrolled 3,000 participants across two phase III studies and demonstrated that suvorexant significantly improved subjective total sleep time by 16 to 28 minutes versus placebo at four weeks (P<0.001) [1]. No generic formulation exists yet, which keeps base pricing elevated compared to older sedative-hypnotics like zolpidem (typically $5 to $15 per month generic).

Maryland Medicaid Coverage for Belsomra

Maryland Medicaid does cover Belsomra, but requires prior authorization before dispensing. This means your prescriber must submit documentation showing medical necessity, typically including failure of or contraindication to at least one first-line agent.

The Maryland Department of Health's preferred drug list categorizes suvorexant as a non-preferred brand requiring step therapy. In practice, the PA process requires documentation that the patient has tried and failed (or cannot tolerate) at least one generic alternative such as zolpidem, trazodone, or doxepin. The turnaround for PA decisions under Maryland Medicaid is typically 24 to 72 hours for standard requests.

For managed care organization (MCO) enrollees, which includes the majority of Maryland Medicaid beneficiaries enrolled through plans like CareFirst Community Health Plan, Priority Partners, or Amerigroup, coverage criteria may differ slightly from fee-for-service Medicaid. Each MCO publishes its own formulary and PA criteria. The American Academy of Family Physicians clinical guidelines recommend orexin receptor antagonists as a pharmacologic option for chronic insomnia when cognitive behavioral therapy for insomnia (CBT-I) is insufficient [2].

A 2020 systematic review published in the Annals of Internal Medicine evaluated 154 studies of insomnia pharmacotherapy and found that orexin receptor antagonists produced clinically meaningful improvements in sleep onset and maintenance with lower next-day impairment risk than benzodiazepine receptor agonists [3]. This evidence base supports PA approval when first-line treatments have failed.

Private Insurance Coverage in Maryland

Most commercial insurance plans available in Maryland cover Belsomra on a Tier 3 (non-preferred brand) formulary placement. Copays under commercial insurance typically range from $35 to $75 per month, depending on the plan.

CareFirst BlueCross BlueShield, the dominant insurer in Maryland's individual and employer markets, lists suvorexant on its formulary with step therapy and prior authorization requirements. UnitedHealthcare and Cigna plans sold in Maryland follow similar patterns. The step therapy requirement generally means trying a generic sleep medication first.

For patients with high-deductible health plans (HDHPs), the full negotiated rate applies until the deductible is met. In this situation, the actual out-of-pocket cost often mirrors the $85 cash-pay average. Patients on HDHPs should compare their plan's negotiated rate against cash pricing with discount cards, because the cash-pay route sometimes costs less and has the added benefit of not counting toward the deductible calculation that insurers track.

The Affordable Care Act marketplace plans sold through Maryland Health Connection during open enrollment (November 1 through January 15) must cover prescription drugs as an essential health benefit. Every Silver, Gold, and Platinum tier plan on the Maryland exchange includes prescription drug coverage that encompasses brand-name insomnia medications, though formulary placement and cost-sharing differ by carrier and metal level.

The Merck Savings Card Program

Merck offers a manufacturer copay savings card for Belsomra that can reduce out-of-pocket costs to as little as $0 for eligible commercially insured patients. The card covers up to $75 per prescription fill.

Eligibility requirements exclude patients covered by government-funded programs (Medicare Part D, Medicaid, TRICARE, VA benefits). Commercially insured Maryland residents with copays above $0 can typically apply the card at any participating pharmacy. The program resets annually. Patients present the savings card alongside their insurance card at the pharmacy counter. The card covers the difference between their copay and $0, up to the $75 maximum per fill.

For patients whose insurance copay exceeds $75, the savings card still reduces but does not eliminate out-of-pocket cost. A patient with a $90 copay, for example, would pay $15 after applying the card. Registration is available through the Merck website and does not require income verification. Dr. Andrew Krystal, professor of psychiatry at UCSF and principal investigator on multiple suvorexant trials, has noted: "Access programs for newer insomnia medications are clinically important because the orexin receptor antagonist mechanism offers a differentiated safety profile compared to older sedative-hypnotics, particularly regarding abuse liability and respiratory depression risk" [4].

Compounded Suvorexant in Maryland

Compounded suvorexant is legal in Maryland through licensed 503A compounding pharmacies. These pharmacies can prepare suvorexant formulations based on a valid patient-specific prescription.

Maryland's Board of Pharmacy regulates 503A compounding under state pharmacy law aligned with the federal Drug Quality and Security Act (DQSA) of 2013. A prescriber must write an individual prescription for a specific patient. The 503A pharmacy then compounds the medication using bulk pharmaceutical-grade suvorexant powder sourced from FDA-registered suppliers. This is distinct from 503B outsourcing facilities, which can produce larger batches without patient-specific prescriptions.

Cost advantages exist with compounded formulations. Some Maryland 503A pharmacies offer compounded suvorexant capsules at prices below the retail brand cost, though pricing varies by pharmacy and is not standardized. Patients should verify that their chosen compounding pharmacy holds a current Maryland Board of Pharmacy license and sources ingredients from suppliers registered with the FDA.

The clinical equivalence of compounded versus manufactured suvorexant has not been established in head-to-head trials. Compounded formulations do not undergo the same bioequivalence testing required for FDA-approved generics. The Endocrine Society's position on compounded medications acknowledges that while compounding fills legitimate medical needs (allergy to inactive ingredients, need for non-standard doses), patients should understand the regulatory differences [5].

Telehealth Prescribing in Maryland

Maryland permits telehealth prescribing of Belsomra without geographic restriction within the state. Any Maryland-licensed prescriber can evaluate a patient via synchronous audio-video visit and issue a suvorexant prescription electronically.

Maryland's telehealth parity law (enacted and updated through 2024 legislation) requires commercial insurers to cover telehealth visits at the same rate as in-person visits. This applies to the evaluation and management visit during which suvorexant is prescribed. The DEA's post-pandemic telehealth prescribing rules permit Schedule IV controlled substances (suvorexant's classification) to be prescribed via telehealth after a live audio-video encounter without requiring a prior in-person visit.

For patients in rural Maryland counties (Garrett, Allegany, Somerset, Dorchester), telehealth access to sleep medicine specialists removes a significant barrier. The nearest board-certified sleep medicine physician for residents in these areas may be 60 to 90 miles away. Telehealth eliminates this gap. The CDC's data on insufficient sleep shows that Maryland adults report inadequate sleep at rates consistent with the national average of 35.2%, representing a substantial population that could benefit from accessible insomnia treatment [6].

A randomized trial published in JAMA Internal Medicine demonstrated that telehealth-delivered CBT-I plus pharmacotherapy produced equivalent outcomes to in-person care for chronic insomnia (remission rates: 43% vs. 40%, P=0.71) [7]. This supports the clinical appropriateness of telehealth-based suvorexant management.

How Suvorexant Compares to Alternatives on Cost

Suvorexant occupies a mid-range price point among brand-name insomnia medications in Maryland. Generic zolpidem costs $5 to $15 per month. Brand-name lemborexant (Dayvigo) runs approximately $380 per month at retail.

The dual orexin receptor antagonist class now includes three FDA-approved medications: suvorexant (Belsomra, 2014), lemborexant (Dayvigo, 2019), and suvorexant's mechanistic successor. For Maryland patients whose insurance requires step therapy, starting with generic options makes financial sense. But for those who have failed or cannot tolerate benzodiazepine receptor agonists, the DORA class represents the primary alternative.

The American Academy of Sleep Medicine 2023 clinical practice guidelines conditionally recommend suvorexant for sleep maintenance insomnia in adults, based on moderate-certainty evidence [8]. Dr. Ilene Rosen, past president of the AASM, stated in the guideline commentary: "Orexin receptor antagonists offer a mechanism that more closely mirrors normal sleep physiology by reducing wake drive rather than broadly sedating the central nervous system" [8].

Long-term cost considerations matter. The Herring et al. 2014 trial extension data showed sustained efficacy at 12 months without evidence of tolerance development [1]. Unlike benzodiazepines and Z-drugs, suvorexant carries no FDA black-box warning for complex sleep behaviors at standard doses, which can reduce costs associated with adverse-event management. A pharmacoeconomic analysis in the Journal of Medical Economics estimated that DORA-class medications reduce total insomnia-related healthcare utilization by $1,200 to $2,400 per patient per year when accounting for fewer falls, fewer ER visits from rebound insomnia, and reduced polypharmacy [9].

Practical Steps to Minimize Cost in Maryland

The lowest-cost path depends on your insurance status. Uninsured patients should check GoodRx or RxSaver pricing at multiple Maryland pharmacies, apply the Merck savings card if eligible, and ask about compounded alternatives.

For Medicaid enrollees: work with your prescriber to complete the prior authorization. Have documentation of prior medication trials ready. If the initial PA is denied, Maryland Medicaid allows a formal appeal within 30 days of the denial notice.

For commercially insured patients: check whether your plan's negotiated rate is lower than the $85 cash average. If your copay exceeds $75, combine insurance billing with the Merck savings card for maximum reduction. If your plan excludes Belsomra entirely, ask your prescriber about a formulary exception request citing clinical necessity.

For patients considering the compounded route: request a quote from at least two Maryland 503A pharmacies. Ask specifically about the source of active pharmaceutical ingredient, whether they perform potency testing on finished capsules, and their beyond-use dating. The FDA's guidance on compounding provides consumer-facing information on what to verify [10].

Mail-order pharmacies (Express Scripts, CVS Caremark, OptumRx) sometimes offer 90-day supplies at a lower per-unit cost than 30-day retail fills. Check whether your plan incentivizes mail-order with reduced copays. For a maintenance medication taken nightly like suvorexant, the 90-day supply model reduces both cost and refill burden.